Beneficial effect of human anti-amyloid-b active immunization on neurite morphology and tau pathology
نویسندگان
چکیده
1 MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Massachusetts Alzheimer Disease Research Center, Harvard Medical School, Building 114, 16th Street, 02129-4404, Charlestown, MA, USA 2 Servicio de Neurologı́a, Instituto de Biomedicina de Sevilla (IBiS), Hospitales Universitarios Virgen del Rocı́o, Av. Manuel Siurot s/n 41013 Seville, Spain 3 Institut Neuropatologia-Servei Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat, 08907 Barcelona, Spain 4 Service d’Anatomie Pathologique et Histologie-Cytologie, CHU de Toulouse, Faculté de Médicine Rangueil, INSERM U858, 31432 Toulouse, France 5 Université Lille Nord de France, INSERM U837, F-59000 Lille, France 6 Division of Psychiatry Research, University of Zurich, 8008 Zurich, Switzerland 7 Department of Neuroscience and Department of Pathology, University of California-San Diego School of Medicine, La Jolla, 92093-0624 CA, USA 8 C. S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, 55 Fruit Street, 02114, Boston, MA, USA
منابع مشابه
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.
Anti-amyloid-beta immunization leads to amyloid clearance in patients with Alzheimer's disease, but the effect of vaccination on amyloid-beta-induced neuronal pathology has not been quantitatively examined. The objectives of this study were to address the effects of anti-amyloid-beta active immunization on neurite trajectories and the pathological hallmarks of Alzheimer's disease in the human h...
متن کاملA subcutaneous cellular implant for passive immunization against amyloid-b reduces brain amyloid and tau pathologies
Passive immunization against misfolded toxic proteins is a promising approach to treat neurodegenerative disorders. For effective immunotherapy against Alzheimer’s disease, recent clinical data indicate that monoclonal antibodies directed against the amyloid-b peptide should be administered before the onset of symptoms associated with irreversible brain damage. It is therefore critical to devel...
متن کاملAnti-Aß immunotherapy in Alzheimer's disease; relevance of transgenic mouse studies to clinical trials
Therapeutic approaches to the treatment of Alzheimer's disease are focused primarily on the Aß peptide which aggregates to form amyloid deposits in the brain. The amyloid hypothesis states that amyloid is the precipitating factor that results in the other pathologies of Alzheimer's, namely neurofibrillary tangles and neurodegeneration, as well as the clinical dementia. One such therapy that has...
متن کاملLithium Treatment of APPSwDI/NOS2−/− Mice Leads to Reduced Hyperphosphorylated Tau, Increased Amyloid Deposition and Altered Inflammatory Phenotype
Lithium is an anti-psychotic that has been shown to prevent the hyperphosphorylation of tau protein through the inhibition of glycogen-synthase kinase 3-beta (GSK3β). We recently developed a mouse model that progresses from amyloid pathology to tau pathology and neurodegeneration due to the genetic deletion of NOS2 in an APP transgenic mouse; the APPSwDI/NOS2-/- mouse. Because this mouse develo...
متن کاملHuman tau increases amyloid b plaque size but not amyloid b-mediated synapse loss in a novel mouse model of Alzheimer’s disease
Alzheimer’s disease is characterized by the presence of aggregates of amyloid beta (Ab) in senile plaques and tau in neurofibrillary tangles, as well as marked neuron and synapse loss. Of these pathological changes, synapse loss correlates most strongly with cognitive decline. Synapse loss occurs prominently around plaques due to accumulations of oligomeric Ab. Recent evidence suggests that tau...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010